Major Depressive Disorder Stocks List

Major Depressive Disorder Stocks Recent News

Date Stock Title
Nov 21 PFE Optimism over global healthcare sector rises: Jefferies
Nov 21 PFE Major companies that are also popular short-selling stocks
Nov 21 PFE 5 Best Value Stocks With Discounted PEG to Boost Your Portfolio Return
Nov 21 PFE The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair
Nov 21 PFE Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Nov 21 PFE 2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Nov 21 BDRX Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
Nov 21 PFE EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
Nov 21 PFE 2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Nov 20 PFE CDC warns of an imminent spike in COVID, flu cases
Nov 20 PFE 5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
Nov 20 PFE Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief
Nov 20 PFE Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
Nov 20 PFE Pfizer names head of oncology as new R&D chief
Nov 20 PFE Pfizer Announces New Chief Scientific Officer and President, Research & Development
Nov 20 PFE Pfizer names oncology head Chris Boshoff as R&D chief
Nov 20 PFE Pfizer Names New R&D Chief
Nov 20 PFE Pfizer, under pressure to change, names oncology head as new R&D chief
Nov 20 PFE Is It Time to Sell Eli Lilly and Pfizer Stocks?
Nov 20 PFE European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
Major Depressive Disorder

Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations. It is often accompanied by low self-esteem, loss of interest in normally enjoyable activities, low energy, and pain without a clear cause. People may also occasionally have false beliefs or see or hear things that others cannot. Some people have periods of depression separated by years in which they are normal, while others nearly always have symptoms present. Major depressive disorder can negatively affect a person's personal life, work life, or education, as well as sleeping, eating habits, and general health. Between 2–8% of adults with major depression die by suicide, and about 50% of people who die by suicide had depression or another mood disorder.The cause is believed to be a combination of genetic, environmental, and psychological factors. Risk factors include a family history of the condition, major life changes, certain medications, chronic health problems, and substance abuse. About 40% of the risk appears to be related to genetics. The diagnosis of major depressive disorder is based on the person's reported experiences and a mental status examination. There is no laboratory test for major depression. Testing, however, may be done to rule out physical conditions that can cause similar symptoms. Major depression is more severe and lasts longer than sadness, which is a normal part of life. The United States Preventive Services Task Force (USPSTF) recommends screening for depression among those over the age 12, while a prior Cochrane review found that the routine use of screening questionnaires have little effect on detection or treatment.Typically, people are treated with counseling and antidepressant medication. Medication appears to be effective, but the effect may only be significant in the most severely depressed. It is unclear whether medications affect the risk of suicide. Types of counseling used include cognitive behavioral therapy (CBT) and interpersonal therapy. If other measures are not effective, electroconvulsive therapy (ECT) may be considered. Hospitalization may be necessary in cases with a risk of harm to self and may occasionally occur against a person's wishes.Major depressive disorder affected approximately 216 million people (3% of the world's population) in 2015. The percentage of people who are affected at one point in their life varies from 7% in Japan to 21% in France. Lifetime rates are higher in the developed world (15%) compared to the developing world (11%). It causes the second most years lived with disability, after lower back pain. The most common time of onset is in a person's 20s and 30s. Females are affected about twice as often as males. The American Psychiatric Association added "major depressive disorder" to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in 1980. It was a split of the previous depressive neurosis in the DSM-II, which also encompassed the conditions now known as dysthymia and adjustment disorder with depressed mood. Those currently or previously affected may be stigmatized.

Browse All Tags